Novavax (NVAX) Receivables - Net (2010 - 2026)

Novavax's Receivables - Net history runs 15 years deep, the most recent figure standing at $23.3 million for Q1 2026.

• On a quarterly basis, Receivables - Net fell 55.33% year-over-year to $23.3 million in Q1 2026; TTM through Mar 2026 was $23.3 million, a 55.33% decrease from a year earlier, with the FY2025 full-year figure at $106.4 million, down 8.2% from the prior year.
• Receivables - Net slipped to $23.3 million in Q1 2026 per NVAX's latest filing, from $95.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $478.2 million in Q1 2022 and bottomed at $23.3 million in Q1 2026.
• The 5-year median for Receivables - Net is $108.3 million (2024), against an average of $151.3 million.
• Across the five-year window, Receivables - Net surged 740.37% in 2022 and slumped 90.12% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $96.2 million in 2022, then soared by 216.93% to $304.9 million in 2023, then slumped by 64.49% to $108.3 million in 2024, then retreated by 11.71% to $95.6 million in 2025, then tumbled by 75.62% to $23.3 million in 2026.
• Per Business Quant, the three latest NVAX Receivables - Net figures stand at $23.3 million (Q1 2026), $95.6 million (Q4 2025), and $41.8 million (Q3 2025).